During these critical and unprecedented circumstances for all mankind, Pharmathen and its employees, having as our mission to preserve health, the fundamental asset of all societies, consider as our foremost duty to contribute by all means to the protection of public health and our society.
Participating in CPhI Worldwide 2019 was highly successful for Pharmathen!
On Wednesday, the 6th of November 2019, we were honored to receive this year’s “Salus Index Award”.
Pharmathen is delighted to announce that it has been shortlisted as one of the finalists for the “Global Generics & Biosimilars Awards 2019”. These awards aim at rewarding ‘best practice’ in the two industries, while, at the same time, encouraging improvements in every aspect of the way business is conducted.
The new plant is part of the company’s total investment plan of over €250 million for the next five years, which will lead to the creation of at least 300 new jobs. Sapes – Rodopi, the 6th of September, 2019. Pharmathen’s new Long-Acting Injectables Unit was officially launched today by the Minister of Development and Investments, Mr. Adonis Georgiadis; during a ceremony attended by representatives of the central and local government, the scientific and business community, and the Media.
For yet another year, Pharmathen participates in CPhI Worldwide exhibition 2019 in Frankfurt @Stand No 80C72.
For yet another year, we received the “Diamonds of the Greek Economy” distinction at the business...
Another great distinction for our company!
We are proud of our legal team’s distinction to be among the “Legal 500 2019 General Counsel Powerlist: Greece & Cyprus” that were honored in a reception that took place in Athens on 16 May 2019.
Pharmathen proceeded to new investments and acquired an additional 27-acres land in the Industrial Park of Sapes in order to expand its innovative business.
Pharmathen’s press event for its 50-years milestone
Coming together from all around the globe, we celebrated with our people 50 years of operation...
For yet another year, Pharmathen has been distinguished at the “2018 EU Industrial R&D Investment Scoreboard” and is ranked first among Greek companies based on R&D spending, by investing 33% of its turnover. With annual R&D spending of 49.9 million euros in the 2017-2018 period, Pharmathen ranked 396th on this year’s list of 1,000 companies in the EU with the highest R&D expenditure.
Our participation in CPhI 2018 Worldwide, the world's largest pharmaceutical exhibition, has been a great opportunity for our executives to meet and interact with hundreds of customers and partners coming from around the globe.
For yet another year, Pharmathen participates at CPHI 2018 in Madrid @Stand No 9F31. We look forward to see you there!
Amsterdam, 30/11/2017: Pharmathen, a BC Partners portfolio company, announces the sale of its Greek commercial operations as part of its long-term strategy to become a leader focused on the development of innovative and complex pharmaceuticals.
For yet another year, Pharmathen had an impressive presence at the international exhibition CPhI Worldwide 2017 which took place in Frankfurt, Germany on the 24-26 October 2017.
The Management of Pharmathen announces the signing of a partnership agreement in principle for the acquisition of a majority stake of shares of the Group from the investment group BC Partners. Katsos family remains in the Pharmathen Group, keeping a significant stake of shares and the management of the group.
Ranking even higher among companies that are distinguished for their investments in Research on the basis of the 2014 EU Industrial R&D Investment Scoreboard.
The first funding provided to a private Greek company by the European Investment Bank - ΕΙΒ has been secured by Pharmathen to support its programme concerning the Research and Development of innovative products.
The Greek Pharmaceutical Industry Pharmathen has taken its place on the world map of innovation in the pharmaceutical field, following the most recent achievement by the department of Research and Development of innovative healthcare products, that concerns the development of Long Acting Injectable (LAI) Technology – sustained-release injectable products.